drug · antibody

PRALUENT

updated 3mo ago

by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Antibody drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 6 investigational indications.

targets

Proprotein convertase subtilisin/kexin type 9

all catalysts(0)

nothing on the calendar yet

Trials studying PRALUENT

phase2A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemiarecruitingn=420
—Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)active not recruitingn=2,214
phase2PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lungactive not recruitingn=60
phase2TOP 2301: Neoadjuvant Chemo for NSCLCsuspendedn=126
—Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russiarecruitingn=2,382
phase1Alirocumab in Patients with Sepsiscompletedn=50
—Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patientsrecruitingn=10,000

News(2)

Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
biospace · 29d ago
Gene editing developer Scribe plots an IPO
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.
biopharma_dive · 1mo ago

brand

PRALUENT

trade names

Praluent

generic

ALIROCUMAB

MOA

12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (LDL) receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.

indication

1 INDICATIONS AND USAGE PRALUENT ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death, myocardial infarction, stroke, or unstable angina requiring hospitalization) in adults at increased risk for these events . As an adjunct to diet and exercise to reduce low- density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). adults with homozygous familial hypercholesterolemia (HoFH). PRALUENT is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death, myocardial infarction, stroke, or unstable angina requiring hospitalization) in adults at increased risk for these events. ( 1 ) As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in : adults with hypercholesterolemia ( 1 ) adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). ( 1 ) adults with homozygous familial hypercholesterolemia (HoFH). ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 16m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(2)

Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor

Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.

biospace · 29d ago

Gene editing developer Scribe plots an IPO

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.

biopharma_dive · 1mo ago

PRALUENT

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying PRALUENT

News(2)

Report a data issue

comments(0)

PRALUENT

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying PRALUENT

News(2)

Report a data issue

comments(0)